Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit

NCT03021486 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03021486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03021486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 5, 2017
Completion date
June 30, 2027
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant neoplasm, delirium, locally advanced malignant neoplasm, metastatic malignant neoplasm, recurrent malignant neoplasm